Board of Directors Authorizes New $50 Million Share Repurchase Program BRISBANE, Calif., June 03, 2025–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the repurchase